TOLREMO Raises CHF 2.4 Million in Seed Financing

Zurich, September 18th 2017. TOLREMO therapeutics AG (“TOLREMO”), a privately held research-stage biotechnology company, announced today the completion of a fundraiser with private investors of 2.4 million Swiss Francs. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.